These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26332018)

  • 1. A quantitative proteomics analysis of MCF7 breast cancer stem and progenitor cell populations.
    Nie S; McDermott SP; Deol Y; Tan Z; Wicha MS; Lubman DM
    Proteomics; 2015 Nov; 15(22):3772-83. PubMed ID: 26332018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single Amino Acid Variant Profiles of Subpopulations in the MCF-7 Breast Cancer Cell Line.
    Tan Z; Nie S; McDermott SP; Wicha MS; Lubman DM
    J Proteome Res; 2017 Feb; 16(2):842-851. PubMed ID: 28076950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semi-quantitative evaluation of CD44(+) /CD24(-) tumor cell distribution in breast cancer tissue using a newly developed fluorescence immunohistochemical staining method.
    Kai M; Onishi H; Souzaki M; Tanaka H; Kubo M; Tanaka M; Katano M
    Cancer Sci; 2011 Dec; 102(12):2132-8. PubMed ID: 21838786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD49f-positive cell population efficiently enriches colon cancer-initiating cells.
    Haraguchi N; Ishii H; Mimori K; Ohta K; Uemura M; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Doki Y; Mori M
    Int J Oncol; 2013 Aug; 43(2):425-30. PubMed ID: 23708747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant.
    Farnie G; Sotgia F; Lisanti MP
    Oncotarget; 2015 Oct; 6(31):30472-86. PubMed ID: 26421710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiling of normal and malignant breast tissue show CD44high/CD24low phenotype as a predominant stem/progenitor marker when used in combination with Ep-CAM/CD49f markers.
    Ghebeh H; Sleiman GM; Manogaran PS; Al-Mazrou A; Barhoush E; Al-Mohanna FH; Tulbah A; Al-Faqeeh K; Adra CN
    BMC Cancer; 2013 Jun; 13():289. PubMed ID: 23768049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression and significance of CD44(+)ESA(+)CD24(-/low), stem cell markers for breast cancer, in non-small-cell lung carcinoma].
    Lu ZQ; Li HG; Zhang HZ; Fan MJ; Shen XM; He XX
    Ai Zheng; 2008 Jun; 27(6):575-9. PubMed ID: 18570728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. СD44+/CD24- markers of cancer stem cells in patients with breast cancer of different molecular subtypes.
    Chekhun SV; Zadvorny TV; Tymovska YO; Anikusko MF; Novak OE; Polishchuk LZ
    Exp Oncol; 2015 Mar; 37(1):58-63. PubMed ID: 25804234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer.
    Tsang JY; Huang YH; Luo MH; Ni YB; Chan SK; Lui PC; Yu AM; Tan PH; Tse GM
    Breast Cancer Res Treat; 2012 Nov; 136(2):407-17. PubMed ID: 23053657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability.
    Croker AK; Goodale D; Chu J; Postenka C; Hedley BD; Hess DA; Allan AL
    J Cell Mol Med; 2009 Aug; 13(8B):2236-2252. PubMed ID: 18681906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
    Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
    Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
    J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone.
    Ling LJ; Wang S; Liu XA; Shen EC; Ding Q; Lu C; Xu J; Cao QH; Zhu HQ; Wang F
    Chin Med J (Engl); 2008 Oct; 121(20):1980-6. PubMed ID: 19080260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell-like properties.
    Wang M; Xiao J; Shen M; Yahong Y; Tian R; Zhu F; Jiang J; Du Z; Hu J; Liu W; Qin R
    Int J Cancer; 2011 Jan; 128(1):72-81. PubMed ID: 20232394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of microRNAs in the regulation of breast cancer stem cells.
    Liu S; Clouthier SG; Wicha MS
    J Mammary Gland Biol Neoplasia; 2012 Mar; 17(1):15-21. PubMed ID: 22331423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential gene expression profiling of functionally and developmentally distinct human prostate epithelial populations.
    Liu H; Cadaneanu RM; Lai K; Zhang B; Huo L; An DS; Li X; Lewis MS; Garraway IP
    Prostate; 2015 May; 75(7):764-76. PubMed ID: 25663004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of CD44+/CD24-/low breast cancer stem/progenitor cells to tamoxifen‑ and doxorubicin‑induced autophagy.
    Yenigun VB; Ozpolat B; Kose GT
    Int J Mol Med; 2013 Jun; 31(6):1477-83. PubMed ID: 23589132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
    Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
    Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer stem cell markers - the rocky road to clinical applications.
    Dontu G
    Breast Cancer Res; 2008; 10(5):110. PubMed ID: 18828879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
    Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
    Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.